Introduction: Circulating tumor DNA (ctDNA), which represents an unbiased way to assess tumor genetic profile noninvasively, facilitates studying intratumor heterogeneity. Although intratumor heterogeneity has been elucidated substantially in a few cancer types, including NSCLC, how it influences the ability of tumor cells harboring different genetic abnormalities in releasing their DNA remains elusive. We designed a capture-based panel targeting NSCLC to detect and quantify genetic alterations from plasma samples by using deep sequencing. By applying the panel to paired biopsy and plasma samples, we imputed and compared the ctDNA-releasing efficiency in subclones harboring distinct genetic variants.
driver genes along with numerous genomic aberrations have been identified in NSCLC, resulting in paradigmshifting advances in treatment, with the development of therapies directed at specific genetic alterations, including EGFR, anaplastic lymphoma receptor tyrosine kinase gene (ALK), and ROS1, among others. [8] [9] [10] [11] [12] Such genotyping of tumor tissue allows categorization of patients with respect to optimal treatment regimens. The National Comprehensive Cancer Network guidelines have recommended that multiplex next-generation sequencing (NGS) be performed on tumor tissues from patients with NSCLC to identify their most suitable targeted therapy options and to appropriately counsel patients for clinical trials. 13 Obtaining a genetic profile from tumor biopsy specimens is not only invasive but also biased, owing to its temporal and spatial snapshot nature. In addition, the quality of tissue biopsy specimens obtained from patients who progressed while receiving previous treatment options might not be adequate for NGS testing. [14] [15] [16] Recently, liquid biopsy has received enormous attention and emerged to become a routine diagnostic test thanks to its obvious clinical implications for personalized medicine. 17, 18 Most circulating tumor DNA (ctDNA), which is composed of small fragments of nucleic acid, is released from apoptotic or necrotic tumor cells, thus reflecting the genetic profile of the tumor. 17 Numerous studies have shown that ctDNA can be used as a surrogate for patient stratification, diagnosis, disease monitoring, and identification of resistance mechanisms. 17, 19 In June 2016, the U.S. Food and Drug Administration approved first blood-based companion diagnostic kit for selecting patients for Tarceva (erlotinib [Genentech, South San Francisco, CA]), an EFGR inhibitor approved for locally advanced and metastatic NSCLC. However, the extremely low amount of ctDNA in blood samples presents a serious challenge. Currently, many groups are developing more sensitive methods for detecting mutations in ctDNA. For example, Newman et al. introduced cancer personalized profiling by deep sequencing (CAPPSeq), a method for capturing frequently mutated genetic regions using probe hybridization. 20 NGS allows for large-scale parallel sequencing and has proved to be an effective and accurate tool for the parallel profiling of different forms of genetic abnormalities, including mutations, fusions, and amplifications across a large number of genes. 21 Currently, most researchers use the concentration of cell-free DNA (cfDNA) and the maximum mutation allelic fraction (AF) to impute ctDNA concentration. 22 The mutation AFs of different genetic variants in ctDNA are often used to represent the clonal makeup of a tumor. Those conventional methodologies are based on the assumption that all subclones have the same DNA-releasing capability, which is challenged by our findings. To interrogate mutations present in the circulation, we designed a ctDNA panel targeting patients with advanced lung cancer, consisting of critical exons and introns among 168 genes and covering multiple classes of somatic mutations for detection and quantification of genetic alterations from plasma. We have applied it to matched tumor biopsy and plasma samples of 40 patients with advanced lung cancer. We have illustrated the high clinical feasibility and utility of our capture-based NGS panel in reflecting the genetic profiles of patients with advanced lung cancer. We are also reporting that subclones harboring distinct mutations have differential ability in releasing their DNA. To the best of our knowledge, this is the first time that an association between mutation type and cells' ability to release DNA has been established, adding a novel dimension to tumor heterogeneity.
Materials and Methods

Patient Selection
Between July and August 2015, patients who met the following inclusion and exclusion criteria were enrolled: (1) suspected of having lung cancer or underwent repeat tumor biopsy to direct future treatment; (2) from 18 to 80 years of age; and (3) not eligible for surgery as the first line of multidisciplinary treatment. The exclusion criteria were (1) received a diagnosis of autoimmune disease and (2) received a blood transfusion within a month of commencement of the study. This study was approved by the institutional review board at the Shanghai Chest Hospital. All patients gave informed consent to participate in the study and gave permission for the use of peripheral blood and tumor tissue.
Tumor Tissue Collection, DNA Extraction, and Routine Driver Gene Testing
Patients who had a confirmed diagnosis of lung cancer on the basis of pathologic evaluation of their tumor biopsy samples were enrolled in this study. For each enrolled patient, we collected tumor biopsy and blood samples. DNA was extracted with a QIAamp DNA formalin-fixed paraffin-embedded (FFPE) tissue kit (Qiagen, Valencia, CA) according to the manufacturer's instructions. DNA concentration was measured by the Qubit double-stranded DNA assay (Life Technologies, Carlsbad, CA).
For tissue biopsy samples, the EGFR mutations 19del, L858R, and T790M were assessed by using amplification refractory mutation system polymerase chain reaction (ARMS-PCR) (Amoy Diagnostics, Xiamen, People's Republic of China), ALK fusion was assessed by fluorescence in situ hybridization (FISH) (Abbott-Vysis, Chicago, IL), and ROS1 fusion was assessed by reverse transcriptase quantitative polymerase chain reaction (RT-qPCR). Total RNA extraction from FFPE tissue sections was performed by using the RecoverAll Total Nucleic Acid Isolation Kit for FFPE (Thermo Fisher Scientific, Waltham, MA). RNA was reverse-transcribed by using the ROS1 fusion gene detection kit (Amoy Diagnostics) following the manufacturer's instructions.
Preparation of Plasma cfDNA
At the time of biopsy, 10 mL of peripheral blood was obtained, stored in tubes containing ethylenediaminetetraacetic acid, and incubated at room temperature for 2 hours. The supernatant was transferred to 15-mL centrifuge tubes and centrifuged for 10 minutes at 16,000 g and 4 C. The supernatant was then transferred to a new tube and stored at À80
C for further analysis. Circulating cfDNA was recovered from 4 to 5 mL of plasma by using the QIAamp Circulating Nucleic Acid kit (Qiagen). Quantification of cfDNA was assessed with the Qubit 2.0 fluorimeter (Thermo Fisher Scientific). A minimum of 50 ng of cfDNA is required for construction of an NGS library.
NGS Library Preparation
DNA shearing was performed with a Covaris M220 focused ultrasonicator (Covaris, Inc., Woburn, MA) followed by end repair, phosphorylation, and adaptor ligation. Fragments with a size of 200 to 400 base pairs (bp) were selected by using Agencourt AMPure beads (Beckman Coulter, Fullerton, CA) followed by hybridization with capture probes baits, hybrid selection with magnetic beads, and PCR amplification. A high-sensitivity DNA assay was performed to assess the quality and size of the fragments, and indexed samples were sequenced on a Nextseq500 sequencer (Illumina, Inc., San Diego, CA) with paired-end reads.
Sequencing Data Analysis
Sequencing data were mapped to the human genome (hg19) by using Burrows-Wheeler Aligner 0.7.10. Local alignment optimization, variant calling, and annotation were performed with the Genome Analysis Toolkit 3.2 (Broad Institute, Cambridge, MA), MuTect, and VarScan. Plasma samples were compared against patients' own white blood cells (WBCs) to identify somatic variants. Variants were filtered by using the VarScan fpfilter pipeline, with loci with a depth less than 100 filtered out. At least two and five supporting reads were needed for insertions or deletions (INDELs) in plasma and tissue samples, respectively, whereas eight supporting reads were needed for single-nucleotide variants (SNVs) to be called in both plasma and tissue samples. According to the ExAC, 1000 Genomes, dbSNP, and ESP6500SI-V2 databases, variants with a population frequency higher than 0.1% were grouped as single-nucleotide polymorphisms and excluded from further analysis. The remaining variants were annotated with ANNOVAR and SnpEff v3.6. DNA translocation analysis was performed using both Tophat2 and Factera 1.4.3.
Normalizing ctDNA Abundance
We calculated the "normalized" ctDNA abundance by two different methods. First, the maximum allele frequency of all somatic mutations detected in each plasma sample was used as the surrogate of the proportion of ctDNA among all the cfDNA extracted, and the total amount of ctDNA was imputed by multiplying the total ctDNA amount by that proportion. Second, for all mutations that were detected from both tissue and plasma samples, the ratio of the allele frequencies in plasma versus in tissue was calculated, and relative ctDNA abundance was defined as the average allele frequency ratio within each patient, capped at 1.
Statistical Analysis
Frequency, percentage, and mean (range) were presented for descriptive statistics. The sensitivity, specificity, positive predictive value (PPV), and accuracy were calculated by using tumor biopsy samples as references. The t test and Pearson correlation test were applied for continuous variables and binary variables, respectively. Regression analysis was used to confirm the relationship of the allele frequency of mutations detected in tumor tissue and plasma ctDNA. A p value less than 0.05 was considered statistically significant. SPSS 20 software (IBM, Inc., Armonk, NY) was used for statistical analysis.
Results
Patients' Demographic Characters
Of the 49 patients enrolled in this study, 41 underwent a primary biopsy and eight patients underwent a repeat biopsy. A tumor tissue sample and its matching plasma sample were collected from each patient. Of the 49 patients, nine were excluded from NGS analysis: six had no tumor cells in their biopsy samples, two were determined to have early-stage disease and therefore had an operation, and the tumor of the remaining patient was diagnosed as pleural endothelioma (Fig. 1) . Of the 40 patients profiled, 27 were male and 13 were female; their mean age was 59.3 years. Of the 40 tumor biopsy samples, 27 were obtained from metastatic lymph nodes and 13 were primary tumor tissue samples. Twenty-one patients had a history of smoking and 19 were neversmokers. Twenty-five cases were diagnosed as adenocarcinoma (ADC), eight as squamous cell carcinoma, four as NSCLC not otherwise specified, and three as SCLC. Seven patients were determined to have stage IIIA disease, six to have stage IIIB disease, and 27 to have stage IV disease (Table 1) .
Panel Design and Assessment of NGS Data Quality
For the initial implementation of the ctDNA panel, we focused on patients with NSCLC. This ctDNA panel includes genomic regions harboring known driver mutations in NSCLC as well as exons containing recurrent SNVs according to whole exome sequencing data on adenocarcinoma and squamous cell carcinoma from The Cancer Genome Atlas. Recurrence index (RI), the number of unique patients with mutations covered per kilobase of exons, was used as a guideline as previously described. 3 We included regions with an RI of 20 or higher. We excluded the "predicted drivers" regions, which were included in the CAPP-Seq design from the panel, because the inclusion of these regions did not contribute to identifying additional positive samples beyond regions selected by known drivers, maximum coverage, an RI of 30 or higher, and an RI of 20 or higher. In addition, we included regions known to be clinically meaningful albeit possibly rare, such as critical exons of ALK in which resistance mutations occur. Our ctDNA panel, spanning 168 genes, covers 160 kilobases of human genomic regions.
We performed capture-based targeted deep sequencing on 40 matched tumor biopsy and plasma samples by using our panel to discover somatic mutations and used corresponding WBCs as a baseline for germline mutations. We achieved a mean coverage depth of Â1248 across all target regions on all tissues Figure 1 . Schematic design of the clinical study. A total of 49 patients were enrolled in this study, including 41 who underwent a primary biopsy and eight who underwent a repeat tumor biopsy. Tissue samples and matching plasma samples were collected from each patient. Nine patients were excluded from next-generation sequencing (NGS) analysis: six had no tumor cells in their biopsy samples, the disease of two was diagnosed as early stage, and the disease of one was diagnosed as pleural endothelioma. cfDNA, cell-free DNA. samples and mean coverage depths of Â23,881 and Â18,338 for plasma samples and matching WBCs, respectively. Among all samples, the percentage of mapped reads was higher than 99% ( Supplementary  Fig. 1 ). The mean insert sizes for tissue, plasma, and WBCs were 237 bp, 169 bp, and 239 bp, respectively. Next, we assessed the ability of NGS to quantify mutations. We performed pre-experiment of serial dilutions of classic mutations in four genes, serine/threonine kinase 11 gene (STK11), KRAS, tuberous sclerosis 1 gene (TSC1), and tumor protein p53 gene (TP53), from 100% to 1%, and observed an excellent positive correlation between observed and expected allele frequency, highlighting the quantification ability of NGS (Supplementary Fig. 2 ).
Mutation Spectrum in Tissue and Blood Samples
To assess the sensitivity and specificity of the panel for detecting somatic mutations in plasma samples, we applied the panel to both tumor biopsy samples and their matching plasma samples and compared the mutations identified from each source. For tissue biopsy samples, our panel identified mutations in 95% of patients. Two patients (patients 27 and 44) had no mutations identified from the panel. Overall, 118 genetic aberrations were identified in tumor tissue samples, spanning 36 genes, including 82 SNVs, 23 INDELs, nine copy number amplifications, and four translocations. Among all genetic aberration events identified, the oncogenic driver mutations, including EGFR, KRAS, BRAF, and erb-b2 receptor tyrosine kinase 2 gene (ERBB2) mutations and ALK, rearranged during transfection gene (RET), and ROS1 fusions comprised 25.4% of all variants identified. Twenty-seven patients carried oncogenic driver mutations. Most mutations were found in both plasma and tissue samples. A few discrepancies existed and are highlighted in Supplementary Table 1 . Driver mutations demonstrated a complete mutually exclusive relationship, whereas other mutations did not show significant mutual exclusivity either with the driver mutations or with each other (Fig. 2A) .
Across 40 plasma samples, 138 genetic aberrations were identified. When the mutation spectrum of somatic mutations identified in tumor biopsy samples was used as a reference, the by-variant sensitivity was 87.2%, excluding copy number variations (CNVs) and the by-patient sensitivity was 97.4%. One patient (patient 24) had mutations identified in the tumor sample but none in the matching plasma. In contrast, another patient (patient 44) had no mutation identified in the primary tumor tissue, but mutations were identified in the plasma, revealing heterogeneity between blood and biopsy samples (see Fig. 2A ).
The sensitivities for SNVs, INDELs, fusion, and CNVs were 84.1%, 95.7%, 100%, and 44.4%, respectively. Among all variants except CNV, the by-variant sensitivity for the seven most critical and actionable genes in NSCLC, including EGFR, ALK, ROS1, RET, ERBB2, BRAF, and KRAS, was 96.2%. In contrast, when blood was used as a reference, the sensitivities for actionable genes, cell cycle-related genes, and other genes were 92.6%, 86.1%, and 60.9%, respectively (Fig. 2B) .
Next, we assessed the correlation of the allele frequency of mutations detected in tumor tissue and plasma ctDNA. The scatterplot shows the frequency of mutations detected in both tumor biopsy and matching plasma samples (Supplementary Fig. 3 ). Collectively, a high degree of correlation was observed between mutation frequency detected in a tumor and its matching plasma sample, with a r value of 0.44 (p < 0.00001) across all patients. Interestingly, we observed that the sensitivities varied for different types of mutations and different types of genes.
Collectively, 53 discordant mutations between tissue samples and their matched plasma sample were found for 24 of the 40 patients tested. This demonstrates a significantly stronger intrapatient clustering effect than would be expected if the discordance were randomly distributed among all tested patients (p ¼ 0.022), indicating that the cause of the discordance is more biological than technical.
Subclones Harboring Distinct Mutations Have Differential Ability to Release Their DNA
When tissue biopsy samples were used as references, the concordance rate in identifying mutation between biopsy samples and their matching plasma samples differed significantly for different types of genes. A much higher concordance rate (96.2%) was observed for the driver genes. In contrast, the concordance rate for other genes was only 86.7% and for the four cell cycle-related genes, TP53, gene cyclin-dependent kinase inhibitor 2A (CDKN2A), retinoblastoma 1 gene (RB1), and SMAD family member 4 gene (SMAD4), it was 81.6%. We derived a normalized relative AF score (NRAFS) to reflect ctDNAreleasing efficiency. We normalized the AF observed in plasma with the AF in tissue. If multiple mutations were present in a sample, each ratio (AF in plasma divided by AF in tissue) was normalized again with the greatest ratio to obtain a NRAFS. A higher score corresponds to more efficiency in releasing DNA. A comparison of NRAFS among driver genes, other genes, and cell cycle-related genes was performed. Driver genes, including EGFR, KRAS, ALK, BRAF, ERBB2, ROS1, and RET, had a significantly higher NRAFS than others (p ¼ 0.007), and other genes had a higher NRAFS than the cell cycle-related genes (p ¼ 0.066) (Fig. 3A) . Collectively, our data demonstrated that subclones with mutations in driver genes are more prone to release their DNA. In contrast, subclones with mutations in cell cycle-related genes were least likely to release their DNA. To visualize the difference in the releasing capability of different subclones, we selected patients harboring mutations in both driver genes and cell cycle-related genes to construct a spectrum for NRAFS (Fig. 3B) . Subclones with mutations in driver genes have a higher NRAFS, thus reflecting higher capability in releasing DNA.
To further confirm our finding, we expanded our study to another cohort, consisting of 41 treatment-naive patients from seven sites. Of the 41 patients, 37 harbored mutations from our panel in their biopsy samples and were therefore included in our study. We identified 63 mutations, of which 21 belonged to cell cycle pathways and 28 belonged to driver genes. Of the 21 cell cycle-related mutations, 18 belonged to TP53. The mean NRAFS for driver genes, cell cycle-related genes, and others were 0.775, 0.577 and 0.535, respectively. Subclones carrying mutations in driver genes showed a significantly higher releasing efficiency than subclones carrying other mutations (p ¼ 0.037). Collectively, our data demonstrated differential ability in releasing ctDNA among subclones harboring distinct mutations, adding a new dimension to intratumor heterogeneity.
Concordance between Capture-based NGS and Conventional Methods
To assess the performance of the panel, we compared the NGS profiling results of three representative mutations: EGFR, ALK, and ROS1 with conventional methods, ARMS-PCR, fluorescence in situ hybridization (FISH), and RT-qPCR, respectively. Among the 37 samples for which ARMS-PCR was performed for detection of EGFR mutation, ARMS-PCR demonstrated a 100% concordance with NGS ( Supplementary Fig. 4A ). Among the 37 patients for whom FISH was performed for ALK fusion detection, the concordance between FISH and NGS was 97.3% ( Supplementary Fig. 4B ). We further compared detection of ROS1 fusion by using RT-qPCR and NGS and achieved 100% concordance ( Supplementary Fig. 4C ). Collectively, the panel demonstrated an excellent concordance with conventional methods (Supplementary Fig. 4D ).
histologic type, technique used to obtain the tissue biopsy sample, and source of the biopsy sample. We utilized two different methods to assess the association: relative ctDNA abundance and ctDNA concentration. The relative ctDNA abundance was obtained by using mutant AF in plasma to normalize against mutant AF in tumor. ctDNA concentration was imputed by multiplying the total amount of cfDNA obtained by the maximum mutant AF. A t test was performed for binary variables and a Pearson correlation test was performed for continuous variables. Both relative ctDNA abundance and ctDNA concentration showed a significant correlation with disease M stage ( Table 2 and Fig. 4) .
Discussion
Gene abnormalities, especially those resulting in tumorigenesis (e.g., abnormalities in EGFR, ALK, and others) are important biomarkers in NSCLC, and the National Comprehensive Cancer Network guidelines suggest detecting gene abnormalities to direct personal therapy. 17 Detection of such abnormalities in peripheral blood rather than in tumor tissue has received enormous attention because of its convenience and noninvasiveness, as well as because of the obvious clinical implications for cancer detection and direction of personalized therapy. Previous studies have indicated that ctDNA, circulating tumor cells, and microRNA in peripheral blood can reflect the gene abnormalities in the primary tumor, including gene mutations, microsatellite instabilities, gene hypermethylation, and others. [23] [24] [25] [26] [27] [28] In this prospective single-center study, we assessed the technical performance of our ctDNA panel in detecting and quantifying mutations by applying it to both tumor biopsy samples and matching plasma samples form 40 patients with advanced lung cancer. In general, our panel presented great concordance between the paired tissue and plasma samples, illustrating its high clinical feasibility and utility. The by-variant specificity was higher than 99% for all genes and all variant types. The by-variant sensitivity was 87.2%, excluding for CNVs, in which case it increases to 96.6% for the seven actionable genes.
Some discordance between tumor and blood samples was apparent when gene abnormalities were found in either tumor tissue or peripheral blood but not in both. Mutations detected only in blood samples and not in tumor biopsy samples can be attributed to the heterogeneity observed in lung cancer; therefore, biopsy samples obtained from different parts of a tumor may harbor different types of mutations. 29 In contrast, detection of mutations only in tumor biopsy samples and not in blood samples can be attributed to a few factors. It is a wellknown phenomenon that ctDNA is diluted by cfDNA from normal cells; therefore, the ctDNA allele fraction is much lower in plasma than in tumor tissues, 30 necessitating much higher sequencing coverage. Not enough sequencing depth can contribute to not detecting mutations in the circulation. Low tumor content is another contributing factor.
One limitation associated with this study is that evaluation of tumor content was done only for the part of sample used for pathologic evaluation and not done for the part subjected to NGS; therefore, we cannot rule out the possibility of low tumor content in samples in which no mutation was detected. In addition, we can report a novel mechanism responsible for such discrepancy. We discovered that subclones carrying distinct mutations have differential ability to release their DNA. Subclones harboring driver mutations are more prone to release their DNA than subclones with nondriver mutations. Subclones with TP53, RB1, SAMD4, and CDKN2A mutations are least efficient in releasing to their DNA. To the best of our knowledge, this is the first time this phenomenon has been discovered and reported, adding a new dimension to tumor heterogeneity.
We have also introduced a novel way to present ctDNA abundance. Conventionally, the total amount of ctDNA is often imputed by multiplying total cfDNA amount with the maximum mutant AF. This methodology does not correct for the heterogeneity present in the tumor. We derived relative ctDNA abundance by normalizing the AF of mutations detected in ctDNA with their AF in tumor biopsy samples, thus more accurately reflecting the amount of ctDNA present in the circulation by correcting for tumor heterogeneity.
In summary, our results demonstrate that our ctDNA panel combined with ultradeep sequencing serves as a sensitive and specific method for detecting genetic lesions from plasma, thus highlighting the potential to use peripheral blood as a surrogate. More importantly, we are reporting that subclones harboring distinct mutations have differential ability to release their DNA, which is partially responsible for the discrepancy between mutations detected in tumor biopsy samples and blood samples.
